Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
[i] Sanofi data on file
[ii] Guideline for the management of postmeal glucose. International Diabetes Federation, published 2007
[iii] Riddle M, Umpierrez G, DiGenio A. et al. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1CLevels Before and After Treatment Intensification in Type 2 Diabetes. Diabetes Care, 2011; 34: 2508-2514
[iv] Colclough H., Piercy J., Benford M. Levels of FPG and HbA1c control and the relationship to BMI in T2D patients treated with basal insulin and OAD therapy. Abstract presented at ADA, June 2012
[v] Effects of Intensive Glucose Lowering in Type 2 Diabetes, The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). N Engl J. Med 2008, 358: 2545-2559
[vi] Baxter, M. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol 2008;45:253-268
[vii] American Diabetes Association. Postprandial Blood Glucose. Diabetes Care. 24; 4 (2001)
[viii] Lorenz M., Pfeiffer, C., Steinsträßer, P. et al. Effects of lixisenatide once daily on gastric emptying and its relationship to postprandial glycaemia in Type 2 diabetes mellitus. Poster presented at EASD, October 2012
[ix] Christensen M, Knop F, Vilsbøll T et al. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Rev. Endocrinol. Metab. 6(4), 513–525 (2011)
[x] Pinkney J. et al. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Therapeutics and Clinical Risk Management 2010; 6:401–411
[xi] Reid T. Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. Clinical Diabetes 2012; 30 (1): 3-12
[xii] Diabetes.co.uk. Guide to HbA1c. Access via: http://www.diabetes.co.uk/what-is-hba1c.html Last accessed: June 2012
[xiii] Sneider H, Sawtell PA, Ross L. HbA1c Levels Are Genetically Determined Even in Type 1 Diabetes. Access via: http://diabetes.diabetesjournals.org/content/50/12/2858.full.pdf Last accessed: June 2012
[xiv] Diabetes UK Guide to Type 2 diabetes http://www.diabetes.org.uk/Guide-to-diabetes/Type-2-diabetes/ Last accessed: July 2012
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Sanofi Diabetes. "PPG Is Acknowledged By 70% Of Diabetes Specialists As Being Equally Important To FPG For Achieving HbA1c Goals In Type 2 Diabetes Mellitus." Medical News Today. MediLexicon, Intl., 4 Oct. 2012. Web.
10 Mar. 2014. <http://www.medicalnewstoday.com/releases/251073>
Sanofi Diabetes. (2012, October 4). "PPG Is Acknowledged By 70% Of Diabetes Specialists As Being Equally Important To FPG For Achieving HbA1c Goals In Type 2 Diabetes Mellitus." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/251073.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.